Publication: Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial
Date
Date
Date
Citations
Schadendorf, D., Luke, J. J., Ascierto, P. A., Long, G. V., Rutkowski, P., Khattak, A., Del Vecchio, M., de la Cruz-Merino, L., Mackiewicz, J., Sileni, V. C., Kirkwood, J. M., Robert, C., Grob, J.-J., Dummer, R., Carlino, M. S., Zhao, Y., Kalabis, M., Krepler, C., Eggermont, A., & Scolyer, R. A. (2024). Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial. Journal for ImmunoTherapy of Cancer, 12(3), e007501. https://doi.org/10.1136/jitc-2023-007501
Abstract
Abstract
Abstract
Background: Adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) versus placebo in the phase 3 KEYNOTE-716 study of resected stage IIB or IIC melanoma. At the prespecified third interim analysis (data cut-off, January 4, 2022), the HR for RFS in the overall population was 0.64 (95% CI, 0.50 to 0.84) and the HR for DMFS was 0.64 (95% CI, 0.47 to 0.88). We present a post hoc analysis of efficacy by subtypes defined by histopathologic characteristics. Methods: Patients a
Metrics
Downloads
Views
Additional indexing
Creators (Authors)
- Schadendorf, Dirk
- Luke, Jason John
- Ascierto, Paolo A
- Long, Georgina V
- Rutkowski, Piotr
- Khattak, Adnan
- Del Vecchio, Michele
- de la Cruz-Merino, Luis
- Mackiewicz, Jacek
- Sileni, Vanna Chiarion
- Kirkwood, John M
- Robert, Caroline
- Grob, Jean-Jacques
- Dummer, Reinhard
- Carlino, Matteo S
- Zhao, Yujie
- Kalabis, Mizuho
- Krepler, Clemens
- Eggermont, Alexander
- Scolyer, Richard A
Volume
Volume
Volume
Number
Number
Number
Page range/Item number
Page range/Item number
Page range/Item number
Item Type
Item Type
Item Type
In collections
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Keywords
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Free Access at
Free Access at
Free Access at
Publisher DOI
Metrics
Downloads
Views
Citations
Schadendorf, D., Luke, J. J., Ascierto, P. A., Long, G. V., Rutkowski, P., Khattak, A., Del Vecchio, M., de la Cruz-Merino, L., Mackiewicz, J., Sileni, V. C., Kirkwood, J. M., Robert, C., Grob, J.-J., Dummer, R., Carlino, M. S., Zhao, Y., Kalabis, M., Krepler, C., Eggermont, A., & Scolyer, R. A. (2024). Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial. Journal for ImmunoTherapy of Cancer, 12(3), e007501. https://doi.org/10.1136/jitc-2023-007501
